logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Table GPS-8. Lifetime prevalence of drug use among all adults (aged 15 to 64 years old) in nationwide surveys among the general population [see all tables in this series...]

Part (ii) Survey methods: last survey available for each Member State

CountryGeographical areaYearRef.Collection methodOriginal age rangeOriginal sample sizeAge range all adultsSample size all adultsAge range young adultsSample size young adults
BelgiumNational2004(6)InterviewAll ages1265015-6415-34
BulgariaNational2005(1)Interview18-60103618-60103618-34433
Czech RepublicNational2004(2)Interview18-64352618-64352618-341414
DenmarkNational2005(4)Interview16+1456616-641331016-343583
GermanyNational2003(6)Mail18-59806118-59806118-343775
EstoniaNational2003(2)Mail15-69189115-64646
IrelandNational2002-03(4)Interview15-64491815-64491815-34
GreeceNational (except Aegean and Ionian Islands)2004(3)Interview12-64478115-64435115-342620
SpainNational2005-06(6)Interview15-642793415-642793415-3414699
FranceNational2005(6)Phone12-753051415-642587915-3410855
ItalyNational2005(3)Mail15-642799515-642799515-3416552
CyprusNational2006(1)Interview15-64350415-64350415-341753
LatviaNational2003(1)Interview15-64453415-64453415-34
LithuaniaNational2004(1)Interview15-64420715-64420715-341814
LuxembourgNational1998(1)Interview12-6466715-6415-34
HungaryNational2003(2)Interview18-54367518-5418-342319
MaltaNational2001(1)Interview18-64282818-64175518-34640
NetherlandsNational2005(3)Interview15-64451615-64451615-34
AustriaNational2004(1)Interview14-100454715-64398015-341754
PolandNational2002(1)Interview16+314816-6416-34
PortugalNational2001(1)Interview15-641418615-641418615-346406
RomaniaNational2004(1)Interview15-6415-6415-34
SlovakiaNational2004(2)Interview15-64131515-64131515-34578
FinlandNational2004(6)Mail15-69252615-64235215-341031
SwedenNational2006(7)Mail16-845688916-644170116-3414408
United KingdomEngland and Wales2005-06(9)Interview16-592974816-592974816-3412329
United KingdomNorthern Ireland2002-03(10)Interview15-64351615-64351615-34
United KingdomScotland2004(12)Interview16+442416-64329316-34978
United KingdomUnited Kingdom2004(13)Interview16-34
NorwayNational2004(2)Interview15+319115-64266915-341238

Notes:

 This table presents the methods and results for the last surveys available in each country. The number indicated in the column 'Ref.' is the reference to the corresponding survey in the table presenting all surveys available for each countryTable GPS-0.   

 This table aims to present an overview of national surveys. Exceptionally, some relevant regional surveys are presented. Some city surveys reported by countries were not included as they tend to produce higher prevalence estimates which are not comparable with estimates for whole countries (or large regions with both urban and rural areas). Athens was included as a reference point for the 1993 survey.   

 'Data collection' means 'data collection method used in the survey': 'interview' (face-to-face interview, which may include self-completed sections for the more sensitive questions, also it may include CAPI - computer assisted interviews), 'phone' (telephone interview), 'mail' (mailed questionnaire), 'Multimethod' (Multi-Method - simultaneous use of interview, mail or internet in the same survey).    

  'Survey sample' refers to the number of actual respondents to the survey (Net sample). In some cases, national surveys cover originally a broader age range ('original age range') than that presented here for the standard groups 'All adults'(15-64) and 'Young adults' (15-34). Sample sizes are presented respectively for the 'original age range', the 'all adults' and 'young adults' groups.    

 In surveys with small sample sizes results should be interpreted with caution.   

 Countries were asked to report results using, as far as possible, EMCDDA standard age groups (all adults: 15-64, young adults: 15-34). In countries where age ranges are more restrictive, prevalence estimates may tend to be slightly higher. Some countries have recalculated their prevalence figures using the EMCDDA standard age groups.   

 For methods and definitions on population surveys in general, see General population surveys of drug use – methods and definitions.    

 See also 'General notes for interpreting data' on the Explanatory notes and help page.   

Sources:

 See Table GPS-0.   

 For more details on methodological features for each survey, see Table GPS-20.   

Page last updated: Wednesday, 07 November 2007